# \[Liraglutide in the treatment of diabetes type 2\].

> PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-22165195-liraglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2015-11-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22165195-liraglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22165195-liraglutide-v1.json
- Content SHA-256: `dbf05a533b650b88665d10a866b13a1941f8528f84760b46ef1957558607fd30`

## Claims and source pins

### Headline

\[Liraglutide in the treatment of diabetes type 2\]. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

### Summary

PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

### Paragraph 1

PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`](#source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2))

## Sources

<a id="source-pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2"></a>
- **\[Liraglutide in the treatment of diabetes type 2\]. · retained source version 1:2015-11-19:current:3958cd82efe2e6a7fd0a2bbe05d386371cde63b9da5d0e8ce82659fc55a258cb** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22165195/) (`pubmed-observation-pmid-22165195-2015-11-19-3958cd82efe2`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "\[Liraglutide in the treatment of diabetes type 2\]." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-22165195-liraglutide-v1.json SHA-256: dbf05a533b650b88665d10a866b13a1941f8528f84760b46ef1957558607fd30.